SI-BONE, Inc. SIBN

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation. As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we have developed a deep competency in addressing the challenges of low-density bone in the sacrum. With our additive manufacturing, or 3D-printing, experience developed in sacroiliac fusion, we have established a technology platform that now extends to meet critical unmet needs in thoracolumbar fixation and fusion and pelvic trauma.

We market our products primarily with a direct sales force as well as a number of third-party sales agents in the United States, and with a combination of a direct sales force, sales agents and resellers in other countries. As of December 31, 2025, over 140,000 procedures have been performed using our products since we introduced iFuse in 2009.

Last close 21.48 2026-10-23
Market cap $962.7M 2026-06-30 share count
52-week range 11.48 - 21.89

Valuation FY2025 figures against the last close

P/S4.8x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.44

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $200.9M$167.2M$138.9M$106.4M$90.2M$73.4M$67.3M$55.4M$48.0M—
Cost of revenue $41.0M$35.1M$29.5M$15.7M$10.4M$8.9M$6.8M$4.8M$5.1M—
Gross profit $159.9M$132.1M$109.4M$90.7M$79.7M$64.5M$60.5M$50.5M$42.9M—
R&D $17.4M$16.6M$15.0M$13.6M$12.4M$9.5M$7.3M$5.4M$5.5M—
SG&A $40.5M$33.8M$31.1M$29.0M$25.1M$19.8M$21.0M$12.6M$13.1M—
Total operating expenses $182.2M$167.4M$156.4M$150.3M$131.4M$103.1M$96.5M$62.5M$60.2M—
Operating income -$22.3M-$35.2M-$46.9M-$59.6M-$51.7M-$38.6M-$36.0M-$12.0M-$17.4M—
Interest expense $2.6M$3.4M$3.5M$2.8M$5.4M$6.1M$4.9M$5.1M$6.2M—
Pre-tax income -$18.9M-$30.9M-$43.3M-$61.3M-$56.6M-$43.7M-$38.4M-$17.5M-$23.0M—
Income tax $0$0$0$0$0——$0$0—
Net income -$18.9M-$30.9M-$43.3M-$61.3M-$56.6M-$43.7M-$38.4M-$17.5M-$23.0M—
EPS, basic -0.44-0.75-1.13-1.79-1.71-1.50————
EPS, diluted -0.44-0.75-1.13-1.79-1.71-1.50-1.55-2.20-6.65—
Shares, diluted (wtd. avg.) 43.0M41.5M38.4M34.2M33.1M29.1M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $42.2M$34.9M$33.3M$20.7M$63.4M$53.6M$10.4M$25.1M$22.4M$27.9M
Short-term investments ———$76.6M$83.6M$142.9M$81.3M$97.1M——
Receivables $29.9M$27.5M$22.0M$20.7M$14.2M$13.6M$11.7M$8.5M$7.4M—
Inventory $33.9M$27.1M$20.2M$17.3M$11.5M$5.6M$5.5M$3.3M$2.6M—
Total current assets $216.1M$207.8M$211.4M$137.6M$175.9M$218.2M$111.5M$136.0M$33.6M—
Property, plant and equipment $21.3M$20.4M$16.0M$15.6M$9.0M$4.5M$4.0M$2.2M$1.9M—
Total assets $238.6M$230.4M$230.4M$157.6M$190.5M$223.1M$117.0M$138.5M$35.8M—
Accounts payable $4.6M$6.5M$4.6M$6.3M$3.2M$3.3M$2.8M$2.1M$1.8M—
Short-term debt —————$0$4.4M$0——
Total current liabilities $25.3M$27.1M$23.5M$21.2M$16.9M$13.5M$18.8M$9.0M$7.5M—
Long-term debt $35.6M$35.5M$36.1M$35.2M$35.0M$39.5M$34.9M$39.0M$38.7M—
Total liabilities $61.0M$63.5M$61.0M$59.2M$56.1M$53.8M$54.0M$48.3M$46.7M—
Retained earnings -$450.3M-$431.4M-$400.4M-$357.1M-$295.8M-$239.3M-$195.6M-$157.2M-$139.7M—
Total equity $177.5M$167.0M$169.4M$98.3M$134.4M$169.4M$63.0M$90.2M-$129.4M-$108.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$675.0K-$12.4M-$18.7M-$41.7M-$39.5M-$30.7M-$31.6M-$14.5M-$17.5M—
Depreciation and amortisation $5.8M$4.4M$5.4M$3.5M$2.1M$1.1M$774.0K$722.0K$1.0M—
Stock-based compensation $25.5M$25.9M$24.1M$23.1M$16.9M$11.9M$7.5M$2.3M$1.4M—
Capital expenditure $8.4M$10.5M$7.8M$9.5M$6.4M$2.6M$2.4M$942.0K$478.0K—
Investing cash flow $4.2M$12.6M-$59.8M-$2.8M$51.6M-$62.9M$13.5M-$97.8M-$478.0K—
Financing cash flow $3.4M$2.0M$90.9M$2.2M-$1.7M$136.4M$3.5M$115.2M$12.9M—
Buybacks ——————$38.0K$73.0K$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001459839-26-000049.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100M 0 100M 200M 300M Revenue, FY2017: 48M Gross profit, FY2017: 42.9M Net income, FY2017: -23M Revenue, FY2018: 55.4M Gross profit, FY2018: 50.5M Net income, FY2018: -17.5M Revenue, FY2019: 67.3M Gross profit, FY2019: 60.5M Net income, FY2019: -38.4M Revenue, FY2020: 73.4M Gross profit, FY2020: 64.5M Net income, FY2020: -43.7M Revenue, FY2021: 90.2M Gross profit, FY2021: 79.7M Net income, FY2021: -56.6M Revenue, FY2022: 106.4M Gross profit, FY2022: 90.7M Net income, FY2022: -61.3M Revenue, FY2023: 138.9M Gross profit, FY2023: 109.4M Net income, FY2023: -43.3M Revenue, FY2024: 167.2M Gross profit, FY2024: 132.1M Net income, FY2024: -30.9M Revenue, FY2025: 200.9M Gross profit, FY2025: 159.9M Net income, FY2025: -18.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $48.0M $55.4M $67.3M $73.4M $90.2M $106.4M $138.9M $167.2M $200.9M
Gross profit — $42.9M $50.5M $60.5M $64.5M $79.7M $90.7M $109.4M $132.1M $159.9M
Net income — -$23.0M -$17.5M -$38.4M -$43.7M -$56.6M -$61.3M -$43.3M -$30.9M -$18.9M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Material agreement signed Item 1.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%